PRL and neoplasm: Previous imaging studies have also reported that the greatest reduction in tumour size and serum prolactin levels occurs during the first 3–6 months of treatment, and the lack of significant improvement within this period is a strong predictor of pharmacological resistance to dopamine agonist therapy [53].